An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical TrialsDavid J. Pinato, Sarah P. Blagden, Chara Stavraka et al.|PLoS ONE|2014Cited by 33
Developing an objective marker to optimize patient selection and predict survival benefit in early‐phase cancer trialsChara Stavraka, Sarah P. Blagden, Rebecca Kristeleit et al.|Cancer|2013Cited by 19
Infantile choriocarcinoma treated with chemotherapy aloneEmma Johnson, William H. Wallace, Lynn Myles et al.|Medical and Pediatric Oncology|2003Cited by 18